alagebrium has been researched along with pimagedine in 16 studies
Studies (alagebrium) | Trials (alagebrium) | Recent Studies (post-2010) (alagebrium) | Studies (pimagedine) | Trials (pimagedine) | Recent Studies (post-2010) (pimagedine) |
---|---|---|---|---|---|
83 | 10 | 31 | 2,162 | 18 | 390 |
Protein | Taxonomy | alagebrium (IC50) | pimagedine (IC50) |
---|---|---|---|
Nitric oxide synthase, brain | Homo sapiens (human) | 5.9 | |
Nitric oxide synthase, inducible | Homo sapiens (human) | 4.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (75.00) | 29.6817 |
2010's | 4 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Grill, V; Hiramatsu, S; Inoue, K; Tajirl, Y | 1 |
Kawakami, M; Kuroki, M | 1 |
Cooper, M; Forbes, J; Jerums, G; Osicka, T; Panagiotopoulos, S | 1 |
Foiles, P; Founds, H; Vasan, S | 1 |
Allen, TJ; Burns, WC; Candido, R; Cooper, ME; Deemer, EK; Forbes, JM; Jandeleit-Dahm, KA; Lassila, M; Thallas, V; Thomas, MC; Thorpe, SM; Thorpe, SR; Yee, LT | 1 |
Bach, LA; Boner, G; Cooper, ME; Forbes, JM; Haller, H; Lindschau, C; Meier, M; Rizkalla, B; Thallas-Bonke, V | 1 |
Cui, H; Li, S; Wang, LL; Zhong, W | 1 |
Imaizumi, T; Yamagishi, S | 1 |
Bivalacqua, TJ; Cellek, S; Foxwell, NA; Gur, S; Hellstrom, WJ; Kendirci, M; Usta, MF | 1 |
Chin-Dusting, JP; Cooper, ME; Coughlan, MT; Forbes, JM; Hoang, A; Murphy, AJ; O'Brien, R; Sviridov, D; Thomas, MC | 1 |
Gangula, PR; Jeyabal, PV; Kumar, R; Micci, MA; Pasricha, PJ | 1 |
Barter, PJ; Brown, BE; Davies, MJ; Nobécourt, E; Rye, KA; Yadav, S; Zeng, J | 1 |
Ferrucci, L; Nicklett, EJ; Semba, RD | 1 |
Engelen, L; Schalkwijk, CG; Stehouwer, CD | 1 |
André-Frei, V; Bechetoille, N; Berthod, F; Cadau, S; Leoty-Okombi, S; Pain, S | 1 |
Chao, TF; Chen, YJ; Kao, YH; Lee, TI; Lee, TW | 1 |
8 review(s) available for alagebrium and pimagedine
Article | Year |
---|---|
[Aminoguanidine and other AGE inhibitors].
Topics: Amides; Animals; Arteriosclerosis; Cardiovascular Diseases; Cataract; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Retinopathy; Disease Models, Animal; Drug Design; Glycation End Products, Advanced; Guanidines; Humans; Hydrazines; Hypoglycemic Agents; Thiadiazoles; Thiazoles; Thiazolidines | 2002 |
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Enzyme Inhibitors; Forecasting; Glycation End Products, Advanced; Guanidines; Humans; Protein Kinase C; Ramipril; Renin-Angiotensin System; Thiazoles | 2003 |
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks.
Topics: Aging; Animals; Clinical Trials as Topic; Cross-Linking Reagents; Diabetes Mellitus; Diastole; Drug Evaluation, Preclinical; Elasticity; Glycation End Products, Advanced; Guanidines; Humans; Hypertrophy, Left Ventricular; Molecular Structure; Myocardium; Proteins; Skin; Thiazoles | 2003 |
[Targeted AGEes and AGEs cross-link in drug discovery: preventing and reversing arterial sclerosis in aging and diabetes].
Topics: Aging; Animals; Arteries; Arteriosclerosis; Blood Pressure; Diabetes Mellitus; Glycation End Products, Advanced; Guanidines; Humans; Thiazoles | 2005 |
[Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
Topics: Animals; Clinical Trials as Topic; Depression, Chemical; Diabetic Angiopathies; Glycation End Products, Advanced; Guanidines; Humans; Oxidative Stress; Pyridoxamine; Thiadiazoles; Thiamine; Thiazoles; Thiazolidines | 2005 |
Does accumulation of advanced glycation end products contribute to the aging phenotype?
Topics: Aging; Bone and Bones; Brain; Diet; Enzyme Inhibitors; Erythrocytes; Eye; Food Analysis; Glycation End Products, Advanced; Guanidines; Humans; Inflammation; Kidney; Liver; Longevity; Muscle, Skeletal; Myocardium; Oxidative Stress; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Tendons; Thiazoles | 2010 |
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Enzyme Inhibitors; Evidence-Based Medicine; Female; Glycation End Products, Advanced; Guanidines; Humans; Hyperglycemia; Male; Pyridoxamine; Thiamine; Thiazoles; Treatment Outcome | 2013 |
Therapeutic potential of vitamin D in AGE/RAGE-related cardiovascular diseases.
Topics: Actin Cytoskeleton; Animals; Calcium; Cardiotonic Agents; Diabetic Cardiomyopathies; Gene Expression Regulation; Glycation End Products, Advanced; Guanidines; Humans; Myocardial Reperfusion Injury; Myocarditis; Oxidative Stress; Receptor for Advanced Glycation End Products; Signal Transduction; Thiazoles; Vascular Stiffness; Vitamin D | 2019 |
8 other study(ies) available for alagebrium and pimagedine
Article | Year |
---|---|
Improvement by aminoguanidine of insulin secretion from pancreatic islets grafted to syngeneic diabetic rats.
Topics: Animals; B-Lymphocytes; Diabetes Mellitus, Experimental; Guanidines; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Proinsulin; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Thiazoles; Transplantation, Isogeneic | 2000 |
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
Topics: Actins; Animals; Aorta; Arteriosclerosis; Collagen; Cytokines; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glycation End Products, Advanced; Guanidines; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth; Oxidation-Reduction; Skin; Thiazoles | 2004 |
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Matrix Proteins; Glycation End Products, Advanced; Guanidines; Kidney Cortex; Male; Protein Kinase C; Protein Kinase C-alpha; Protein Transport; Rats; Rats, Sprague-Dawley; Thiazoles | 2004 |
The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dose-Response Relationship, Drug; Glycation End Products, Advanced; Guanidines; Immunohistochemistry; Impotence, Vasculogenic; Male; Rats; Rats, Sprague-Dawley; Streptozocin; Thiazoles | 2006 |
Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.
Topics: Apolipoprotein A-I; Atherosclerosis; ATP-Binding Cassette Transporters; Biological Transport; CD11b Antigen; Cell Line; Cells, Cultured; Cholesterol; Electrophoresis, Polyacrylamide Gel; Glycation End Products, Advanced; Glycosylation; Guanidines; HeLa Cells; Humans; Lipid Metabolism; Lipoproteins, HDL; Phospholipids; Ribose; Thiazoles; Transfection | 2007 |
Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Body Weight; Diabetes Mellitus, Experimental; Duodenum; Enteric Nervous System; Enzyme-Linked Immunosorbent Assay; Glycation End Products, Advanced; Guanidines; Immunohistochemistry; Male; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles | 2008 |
Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.
Topics: Apolipoprotein A-I; Arginine; Cross-Linking Reagents; Glycosylation; Guanidines; Humans; Lipoproteins, HDL; Lysine; Metformin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyridoxamine; Pyruvaldehyde; Thiazoles; Tryptophan | 2008 |
In vitro glycation of an endothelialized and innervated tissue-engineered skin to screen anti-AGE molecules.
Topics: Animals; Capillaries; Cattle; Cell Differentiation; Cells, Cultured; Collagen; Cytoskeleton; Dermis; Endothelial Cells; Fibroblasts; Filaggrin Proteins; Glycation End Products, Advanced; Glycosylation; Glyoxal; Guanidines; Humans; Keratinocytes; Lysine; Mice; Neurons; Protective Agents; Skin; Thiazoles; Tissue Engineering | 2015 |